Tumor necrosis factor-α -308G>A allelic variant modulates iron accumulation in patients with hereditary hemochromatosis

Clinical Chemistry

Volumn 52, Issue 8, 2006, Pages 1552-1558

  Krayenbuehl, Pierre Alexandre ^a   Maly, Friedrich E ^b   Hersberger, Martin ^b   Wiesli, Peter ^a   Himmelmann, Andreas ^a   Eid, Karim ^a   Greminger, Peter ^a   Vetter, Wilhelm ^a   Schulthess, Georg ^a  

^a UNIVERSITY HOSPITAL ZURICH   (Switzerland)

^b UNIVERSITY HOSPITAL ZURICH   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

ADENINE; GUANINE; IRON; TUMOR NECROSIS FACTOR ALPHA;

ADULT; ALLELE; ARTICLE; CLINICAL FEATURE; FEMALE; GENETIC DISORDER; GENETIC VARIABILITY; HEMOCHROMATOSIS; HETEROZYGOTE; HOMOZYGOTE; HUMAN; INTESTINE ABSORPTION; IRON ABSORPTION; IRON DEPLETION; IRON OVERLOAD; LIVER LEVEL; MAJOR CLINICAL STUDY; MALE; MULTIPLE REGRESSION; PHLEBOTOMY; PROTEIN FUNCTION;

ALLELES; FEMALE; HEMOCHROMATOSIS; HETEROZYGOTE; HISTOCOMPATIBILITY ANTIGENS CLASS I; HOMOZYGOTE; HUMANS; IRON; MALE; MEMBRANE PROTEINS; MIDDLE AGED; REGRESSION ANALYSIS; RETROSPECTIVE STUDIES; TUMOR NECROSIS FACTOR-ALPHA; VARIATION (GENETICS);

ANIMALIA;

EID: 33746602284     PISSN: 00099147     EISSN: None     Source Type: Journal    
DOI: 10.1373/clinchem.2005.065417     Document Type: Article

References (54)

1. Feder JN, Gnirke A, Thomas W, Tsuchihashi Z, Ruddy DA, Basava A, et al. A novel MHC class I-like gene is mutated in patients with hereditary hemochromatosis. Nat Genet 1996;13:399-408.
2. Bacon BR, Powell LW, Adams PC, Kresina TF, Hoofnagle JH. Molecular medicine and hemochromatosis: at the crossroads. Gastroenterology 1999;116:193-207.
3. Olynyk JK, Cullen DJ, Aquilia S, Rossi E, Summerville L, Powell LW. A population-based study of the clinical expression of the hemochromatosis gene. N Engl J Med 1999;341:718-24.
4. Bulaj ZJ, Ajioka RS, Phillips JD, LaSalle BA, Jorde LB, Griffen LM, et al. Disease-related conditions in relatives of patients with hemochromatosis. N Engl J Med 2000;343:1529-35.
5. Beutler E, Felitti VJ, Koziol JA, Ho NJ, Gelbart T. Penetrance of 845 G>A (C282Y) HFE hereditary hemochromatosis mutation in the USA. Lancet 2002;359:211-8.
6. Olynyk JK, Luxon BA, Britton RS, Bacon BR. Hepatic iron concentration in hereditary hemochromatosis does not saturate or accurately predict phlebotomy requirements. Am J Gastroenterol 1998;93:346-50.
7. Adams PC, Deugnier Y, Moirand R, Brissot P. The relationship between iron overload, clinical symptoms, and age in 410 patients with genetic hemochromatosis. Hepatology 1997;25:162-6.
8. Bodmer JG, Parham P, Albert ED, Marsh SG. Putting a hold on "HLA-H". The WHO Nomenclature Committee for Factors of the HLA System [Letter]. Nat Genet 1997;15:234-5.
9. Torti SV, Kwak EL, Miller SC, Miller LL, Ringold GM, Myambo KB, et al. The molecular cloning and characterization of murine ferritin heavy chain, a tumor necrosis factor-inducible gene. J Biol Chem 1988;263:12638-44.
10. Tsuji Y, Miller LL, Miller SC, Torti SV, Torti FM. Tumor necrosis factor-α and interleukin 1-α regulate transferrin receptor in human diploid fibroblasts: relationship to the induction of ferritin heavy chain. J Biol Chem 1991;266:7257-61.
11. Alvarez-Hernandez X, Liceaga J, McKay IC, Brock JH. Induction of hypoferremia and modulation of macrophage iron metabolism by tumor necrosis factor. Lab Invest 1989;61:319-22.
12. Scaccabarozzi A, Arosio P, Weiss G, Valenti L, Dongiovanni P, Fracanzani AL, et al. Relationship between TNF-α and iron metabolism in differentiating human monocytic THP-1 cells. Br J Haematol 2000;110:978-84.
13. Gordeuk VR, Ballou S, Lozanski G, Brittenham GM. Decreased concentrations of tumor necrosis factor-α in supernatants of monocytes from homozygotes for hereditary hemochromatosis. Blood 1992;79:1855-60.
14. Hirayama M, Kohgo Y, Kondo H, Shintani N, Fujikawa K, Sasaki K, et al. Regulation of iron metabolism in HepG2 cells: a possible role for cytokines in the hepatic deposition of iron. Hepatology 1993;18:875-80.
15. Han O, Wood RJ. Pro-inflammatory cytokines increase the expression of the HFE protein in human intestinal cells [abstract]. World Congress of Iron Metabolism in Sorrento, Italy 1999;216.
16. Mira JP, Cariou A, Grail F, Delclaux C, Losser MR, Heshmati F, et al. Association of TNF2, a TNF-α promoter polymorphism, with septic shock susceptibility and mortality: a multicenter study. JAMA 1999;282:561-8.
17. McGuire W, Hill AV, Allsopp CE, Greenwood BM, Kwiatkowski D. Variation in the TNF-α promoter region associated with susceptibility to cerebral malaria. Nature 1994;371:508-10.
18. Gonzalez S, Rodrigo L, Martinez-Borra J, Lopez-Vazquez A, Fuentes D, Nino P, et al. TNF-α -308A promoter polymorphism is associated with enhanced TNF-α production and inflammatory activity in Crohn's patients with fistulizing disease. Am J Gastroenterol 2003;98:1101-6.
19. Gao J, Shan G, Sun B, Thompson PJ, Gao X. Association between polymorphism of tumour necrosis factor α-308 gene promoter and asthma: a meta-analysis. Thorax 2006;61:466-71.
20. Schaaf BM, Boehmke F, Esnaashari H, Seitzer U, Kothe H, Maass M, et al. Pneumococcal septic shock is associated with the interleukin-10-1082 gene promoter polymorphism. Am J Respir Crit Care Med 2003;168:476-80.
21. Majetschak M, Obertacke U, Schade FU, Bardenheuer M, Voggenreiter G, Bloemeke B, et al. Tumor necrosis factor gene polymorphisms, leukocyte function, and sepsis susceptibility in blunt trauma patients. Clin Diagn Lab Immunol 2002;9:1205-11.
22. Zipperlen K, Peddle L, Melay B, Hefferton D, Rahman P. Association of TNF-α polymorphisms in Crohn disease. Hum Immunol 2005;66:56-9.
23. Shin HD, Park BL, Kim LH, Jung JH, Wang HJ, Kim YJ, et al. Association of tumor necrosis factor polymorphisms with asthma and serum total IgE. Hum Mol Genet 2004;13:397-403.
24. Francis SE, Camp NJ, Dewberry RM, Gunn J, Syrris P, Carter ND, et al. Interleukin-1 receptor antagonist gene polymorphism and coronary artery disease. Circulation 1999;23;99:861-6.
25. Koch W, Kastrati A, Bottiger C, Mehilli J, von Beckerath N, Schomig A. Interleukin-10 and tumor necrosis factor gene polymorphisms and risk of coronary artery disease and myocardial infarction. Atherosclerosis 2001;159:137-44.
26. Herrmann SM, Ricard S, Nicaud V, Mallet C, Arveiler D, Evans A, et al. Polymorphisms of the tumour necrosis factor-α gene, coronary heart disease and obesity. Eur J Clin Invest 1998;28:59-66.
27. Zeggini E, Groves CJ, Parkinson JR, Halford S, Oven KR, Frayling TM, et al. Large-scale studies of the association between variations at the TNF/LTA locus and susceptibility to type 2 diabetes. Diabetologica 2005;48:2013-7.
28. Sookoian S, Garcia SI, Gianotti TF, Dieuzeide G, Gonzalez CD, Pirola CJ. The G-308A promoter variant of the tumor necrosis factor-α gene is associated with hypertension in adolescents harboring the metabolic syndrome. Am J Hypertens 2005;18:1271-5.
29. Krikovszky D, Vasarhelyi B, Toth-Heyn P, Korner A, Tulassay T, Madacsy L. Association between G-308A polymorphism of the tumor necrosis factor-α gene and 24-hour ambulatory blood pressure values in type 1 diabetic adolescents. Clin Genet 2002;62:474-7.
30. Altarescu G, Zimran A, Michelakakis H, Elstein D. TNF-α levels and TNF-α gene polymorphism in type I Gaucher disease. Cytokine 2005;31:149-52.
31. Jones DE, Watt FE, Grove J, Newton JL, Daly AK, Gregory WL, et al. Tumour necrosis factor-α promoter polymorphisms in primary biliary cirrhosis. J Hepatol 1999;30:232-6.
32. Gordon MA, Oppenheim E, Camp NJ, di Giovine FS, Duff GW, Gleeson D. Primary biliary cirrhosis shows association with genetic polymorphism of tumour necrosis factor α promoter region. J Hepatol 1999;31:242-7.
33. Fargion S, Valenti L, Dongiovanni P, Scaccabarozzi A, Fracanzani AL, Taioli E, et al. Tumor necrosis factor α promoter polymorphisms influence the phenotypic expression of hereditary hemochromatosis. Blood 2001;97:3707-12.
34. Distante S, Elmberg M, Foss Haug KB, Ovstebo R, Berg JP, Kierulf P, et al. Tumour necrosis factor α and its promoter polymorphisms' role in the phenotypic expression of hemochromatosis. Scand J Gastroenterol 2003;38:871-7.
35. Beutler E, Gelbart T. Tumor necrosis factor α promoter polymorphisms and liver abnormalities of homozygotes for the 845G>A(C282Y) hereditary hemochromatosis mutation [Letter]. Blood 2002;100:2268-9.
36. Wilson AG, Symons JA, McDowell TL, McDevitt HO, Duff GW. Effects of a polymorphism in the human tumor necrosis factor α promoter on transcriptional activation. Proc Natl Acad Sci U S A 1997;94:3195-9.
37. Kroeger KM, Carville KS, Abraham U. The -308 tumor necrosis factor-α promoter polymorphism effects transcription. Mol Immunol 1997;34:391-9.
38. Braun N, Michel U, Ernst BP, Metzner R, Bitsch A, Weber F, et al. Gene polymorphism at position -308 of the tumor-necrosis-factor-α (TNF-α) in multiple sclerosis and it's influence on the regulation of TNF-α production. Neurosci Lett 1996;215:75-8.
39. Wu WS, McClain KL. DNA polymorphisms and mutations of the tumor necrosis factor-α (TNF-α) promoter in Langerhans cell histiocytosis (LCH). J Interferon Cytokine Res 1997;17:631-5.
40. Stuber F, Udalova IA, Book M, Drutskaya LN, Kuprash DV, Turetskaya RL, et al. -308 tumor necrosis factor (TNF) polymorphism is not associated with survival in severe sepsis and is unrelated to lipopolysaccharide inducibility of the human TNF promoter. J Inflamm 1996;46:42-50.
41. Brinkman BM, Zuijdeest D, Kaijzel EL, Breedveld FC, Verweij CL. Relevance of the tumor necrosis factor α (TNF α) -308 promoter polymorphism in TNF α gene regulation. J Inflamm 1996;46:32-41.
42. Uglialoro AM, Turbay D, Pesavento PA, Delgado JC, McKenzie FE, Gribben JG, et al. Identification of three new single nucleotide polymorphisms in the human tumor necrosis factor-α gene promoter. Tissue Antigens 1998;52:359-67.
43. Knight JC, Keating BJ, Rockett KA, Kwiatkowski DP. In vivo characterization of regulatory polymorphisms by allele-specific quantification of RNA polymerase loading. Nat Genet 2003;33:469-75.
44. Johnson D, Bayele H, Johnston K, Tennant J, Srai SK, Sharp P. Tumour necrosis factor α regulates iron transport and transporter expression in human intestinal cells. FEBS Letters 2004;573:195-201.
45. Meyer PN, Gerhard GS, Yoshida Y, Yoshida M, Chorney KA, Beard J, et al. Hemochromatosis protein (HFE) and tumor necrosis factor receptor 2 (TNFR2) influence tissue iron levels: elements of a common gut pathway? Blood Cells Mol Dis 2002;29:274-85.
46. Ten Elshof AE, Brittenham GM, Chorney KA, Page MJ, Gerhard G, Cable EE, et al. γδ intraepithelial lymphocytes drive tumor necrosis factor-α responsiveness to intestinal iron challenge: relevance to hemochromatosis. Immunol Rev 1999;167:223-32.
47. Krayenbuehl P, Walczyk T, Schoenberg R, von Blankenburg F, Schulthess G. Hereditary hemochromatosis is reflected in the iron isotope composition of blood. Blood 2005;105:3812-6.
48. Barton JC, McDonnell SM, Adams PC, Brissot P, Powell LW, Edwards CQ, et al. Management of hemochromatosis. Hemochromatosis Management Working Group [Review]. Ann Intern Med 1998;129:932-9.
49. Bacon BR, Olynyk JK, Brunt EM, Britton RS, Wolff RK. HFE genotype in patients with hemochromatosis and other liver diseases. Ann Int Medicine 1999;130:953-62.
50. Vendrell J, Fernandez J-M, Gutierrez C, Zamora A, Simon I, Bardaji A, et al. A polymorphism in the promoter of the tumor necrosis factor-a gene (-308) is associated with coronary heart disease in type 2 diabetic patients. Atherosclerosis 2003;167:257-64.
51. Schuger L, Varani J, Marks RM, Kunkel SL, Johnson KJ, Ward PA. Cytotoxicity of tumor necrosis factor-α for human umbilical vein endothelial cells. Lab Invest 1989;61:62-8.
52. Abraham LJ, Kroeger KM. Impact of the -308 TNF promoter polymorphism on the transcriptional regulation of the TNF gene: relevance to disease. J Leukoc Biol 1999;66:562-6.
53. Hajeer AH, Hutchinson IV. Influence of TNFα gene polymorphisms on TNFα production and disease. Hum Immunol 2001;62:1191-9.
54. Broome U, Eriksson LS, Sundin U, Sundqvist KG. Decreased in vitro production of tumor necrosis factor in primary biliary cirrhosis patients. Scand J Gastroenterol 1992;27:124-8.